CAPLIPOINTPharmaceuticals
Caplin Point Laboratories Ltd — Profit & Loss Statement
₹1504.80
-3.75%
Caplin Point Laboratories Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Normalized Income | 536.31 Cr | 457.08 Cr | 375.48 Cr | 299.84 Cr | — |
| Net Income From Continuing And Discontinued Operation | 536.31 Cr | 457.08 Cr | 376.26 Cr | 299.84 Cr | — |
| Total Expenses | 1.36K Cr | 1.20K Cr | 1.06K Cr | 921.64 Cr | — |
| Diluted Average Shares | 7.63 Cr | 7.63 Cr | 7.65 Cr | 7.64 Cr | — |
| Basic Average Shares | 7.60 Cr | 7.59 Cr | 7.58 Cr | 7.57 Cr | — |
| Diluted EPS | 70.25 | 59.90 | 49.18 | 39.26 | — |
| Basic EPS | 70.57 | 60.19 | 49.62 | 39.61 | — |
| Diluted NI Availto Com Stockholders | 536.31 Cr | 457.08 Cr | 376.26 Cr | 299.84 Cr | — |
| Net Income Common Stockholders | 536.31 Cr | 457.08 Cr | 376.26 Cr | 299.84 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 536.31 Cr | 457.08 Cr | 376.26 Cr | 299.84 Cr | — |
| Minority Interests | -4.78 Cr | -4.33 Cr | -0.73 Cr | -8.61 Cr | — |
| Net Income Including Noncontrolling Interests | 541.09 Cr | 461.42 Cr | 376.99 Cr | 308.45 Cr | — |
| Net Income Continuous Operations | 541.09 Cr | 461.42 Cr | 376.99 Cr | 308.45 Cr | — |
| Tax Provision | 135.69 Cr | 103.01 Cr | 74.36 Cr | 77.37 Cr | — |
| Pretax Income | 676.78 Cr | 564.43 Cr | 451.35 Cr | 385.82 Cr | — |
| Other Non Operating Income Expenses | 96.43 Cr | 66.94 Cr | 3.53 Cr | 38.75 Cr | — |
| Special Income Charges | 0.00 | 0.00 | -0.36 Cr | 0.00 | — |
| Net Non Operating Interest Income Expense | -0.61 Cr | -0.78 Cr | 34.63 Cr | -0.70 Cr | — |
| Interest Expense Non Operating | 0.61 Cr | 0.78 Cr | 0.78 Cr | 0.70 Cr | — |
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.15 Cr | 0.00 | — |
| Tax Rate For Calcs | 0.20 | 0.18 | 0.16 | 0.20 | — |
| Normalized EBITDA | 743.35 Cr | 618.65 Cr | 496.19 Cr | 433.42 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 0.93 Cr | 0.00 | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 0.93 Cr | 0.00 | — |
| Net Income From Continuing Operation Net Minority Interest | 536.31 Cr | 457.08 Cr | 376.26 Cr | 299.84 Cr | — |
| Reconciled Depreciation | 65.96 Cr | 53.44 Cr | 44.99 Cr | 46.90 Cr | — |
| Reconciled Cost Of Revenue | 770.84 Cr | 724.18 Cr | 669.27 Cr | 557.51 Cr | — |
| EBITDA | 743.35 Cr | 618.65 Cr | 497.12 Cr | 433.42 Cr | — |
| EBIT | 677.39 Cr | 565.21 Cr | 452.13 Cr | 386.52 Cr | — |
| Net Interest Income | -0.61 Cr | -0.78 Cr | 34.63 Cr | -0.70 Cr | — |
| Interest Expense | 0.61 Cr | 0.78 Cr | 0.78 Cr | 0.70 Cr | — |
| Operating Income | 580.97 Cr | 498.00 Cr | 398.36 Cr | 347.77 Cr | — |
| Operating Expense | 585.66 Cr | 471.92 Cr | 386.19 Cr | 364.13 Cr | — |
| Other Operating Expenses | 341.98 Cr | 274.89 Cr | 103.17 Cr | 201.93 Cr | — |
| Depreciation And Amortization In Income Statement | 65.96 Cr | 53.44 Cr | 44.99 Cr | 46.90 Cr | — |
| Depreciation Income Statement | 65.96 Cr | 53.44 Cr | 42.64 Cr | 46.90 Cr | — |
| Gross Profit | 1.17K Cr | 969.92 Cr | 784.55 Cr | 711.90 Cr | — |
| Cost Of Revenue | 770.84 Cr | 724.18 Cr | 669.27 Cr | 557.51 Cr | — |
| Total Revenue | 1.94K Cr | 1.69K Cr | 1.45K Cr | 1.27K Cr | — |
| Operating Revenue | 1.94K Cr | 1.69K Cr | 1.45K Cr | 1.27K Cr | — |
| Interest Income | — | 47.28 Cr | 35.41 Cr | 23.50 Cr | 18.61 Cr |
| Rent Expense Supplemental | — | 9.40 Cr | 7.90 Cr | 6.89 Cr | 6.76 Cr |
| Other Special Charges | — | 0.65 Cr | 0.36 Cr | -0.12 Cr | 0.60 Cr |
| Interest Income Non Operating | — | 47.28 Cr | 35.41 Cr | 23.50 Cr | 18.61 Cr |
| Amortization | — | 2.46 Cr | 2.35 Cr | 1.71 Cr | 1.16 Cr |
| Research And Development | — | 73.72 Cr | 63.19 Cr | 59.27 Cr | 53.69 Cr |
| Selling General And Administration | — | 45.27 Cr | 38.69 Cr | 50.40 Cr | 34.63 Cr |
| Selling And Marketing Expense | — | 28.44 Cr | 18.78 Cr | 27.51 Cr | 18.03 Cr |
| General And Administrative Expense | — | 16.83 Cr | 19.91 Cr | 22.89 Cr | 16.60 Cr |
| Rent And Landing Fees | — | 9.40 Cr | 7.90 Cr | 6.89 Cr | 6.76 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Caplin Point Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.